This trial is evaluating whether Pembrolizumab will improve 2 primary outcomes and 2 secondary outcomes in patients with Endometrial Neoplasms. Measurement will happen over the course of 24 months.
This trial requires 25 total participants across 2 different treatment groups
This trial involves 2 different treatments. Pembrolizumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Results from a recent clinical trial provide evidence that uterine fibroids and endometrioid adenocarcinomas have a different phenotype from leiomyomas and are relatively responsive to hormonal treatment.
Endometrial neoplasms form in the lining of the uterus and can occur in a variety of forms. The most common form is endometrial hyperplasia and premalignant lesions (atypical hyperplasia), which can go on to develop into a cancer. Signs of endometrial cancers include abnormal vaginal bleeding for more than a month, abnormal vaginal bleeding with sudden increased weight, painful urination, unexplained weight loss, vaginal bleeding after a fall, infertility, and pain in the back or pelvis. Physicians frequently use the combination of these symptoms, together with abnormal blood tests, to exclude the possibility of an underlying disease.
In the absence of symptomatic symptoms or mass, trans-abdominal or trans-vaginal ultrasound should be done periodically, because it has the highest positivity (100%) for endoscopic or laparoscopic screening and surgery.
Overall [endometrial cancer](https://www.withpower.com/clinical-trials/endometrial-cancer) is a relatively uncommon malignancy in the United States. The incidence rates of the histologic types of endometrial cancer are markedly different: endometrioid is most frequently found in women aged 50 to 60 years; hyperplastic, serous, and mixed endometrioid types occur less frequently but more frequently in those under the age of 40. The annual incidence of endometrial cancer is slightly higher at the end of the fifth decade when compared with the beginning of the fifth decade. Older women have significantly higher rates of cancer.
The symptoms of endometrial neoplasms are nonspecific, and diagnosis is often delayed. Screening for endometrial cancer with CA-125 and serum HE4 determination could aid early diagnosis and appropriate treatment of endometrial neoplasms.
[endometrial cancer](https://www.withpower.com/clinical-trials/endometrial-cancer) occurs in women of all ages. question: Do older women with endometrial cancer have different survival as in younger patients? answer: In this sample of older women, cancer spread and recurrence characteristics were similar to those described in younger women. Survival was poorer, however, and was associated with higher-stage cancers and poorer PS.
A large proportion of endometrial neoplasms (37%) recurred after initial resection with a rate of recurrence exceeding 50% in more than three of seven cases. Survival beyond 1 year after first surgery was significantly better in cases of stage I tumors and endocervical type carcinomas.
A prospective assessment using the three proposed criteria led to a high prevalence of candidates, an indication of how important it is to implement the criteria in clinical practice and an opportunity to analyze the possible use of these criteria in the selection of candidates to clinical trials.
As an anti-CD20 monoclonal antibody, pembrolizumab exerts its anti-inflammatory action in patients with SLE. This may explain the clinical benefit seen in phase III clinical trial, where pembrolizumab was in turn found to be effective at improving SLE disease activity, decreasing the need for systemic corticosteroids, reducing flare rates, and inhibiting the formation of new relapses.
The median age at endometrial carcinoma was 58 years, and at endometrial adenocarcinoma was 65 years. Most patients were Caucasian and over half were postmenopausal. The ratio of endometrial carcinoma to endometrial adenocarcinoma is changing, in part due to the increase in the incidence rate of adenocarcinoma after treatment with radiotherapy.
The use of pembrolizumab (PD-1i) in patients with advanced or metastatic urothelial carcinoma was associated with better antitumor activity as demonstrated by superior clinical response rate, progression-free survival, and overall survival compared with chemotherapy alone or chemotherapy plus pazopanib. Patients who received the treatment of pembrolizumab had a longer survival time compared with the group of patients who received chemotherapy alone or chemo plus pazopanib. Pembrolizumab showed a good safety profile, with no evidence of hepatotoxicity, neoplastic transformation, or serious infections.
In contrast to other hereditary cancers, endometrial neoplasms occur in families rather than singly. The most prevalent types are endometrial stromal tumor and carcinosarcoma and these are found in the same families. Findings from a recent study suggest that there is only limited evidence of an inherited polygenic susceptibility to neoplasm for this rare and devastating disease.